Fulgent Genetics, Inc. ($FLGT) reported its Q4 2025 earnings, with the company’s Chairman and CEO, Ming Hsieh, and Chief Financial Officer, Brandon Perthuis, hosting the earnings call on February 27, 2026. The call detailed the company’s financial performance for the quarter, with $FLGT posting revenue of $141.7 million, representing a 22% increase year-over-year, driven by growth in its genetic testing services.
The earnings call provided insight into $FLGT’s operations, with Hsieh highlighting the company’s expansion into new markets, including China, and the launch of new genetic testing products. Perthuis also discussed the company’s financial outlook, citing a strong balance sheet with $135.6 million in cash and cash equivalents. The company’s stock price has been volatile in recent months, with $FLGT trading at $45.12 as of the close of market on February 27, 2026.
$FLGT’s Q4 2025 earnings report comes as the company continues to navigate the competitive genetic testing market, with major players such as Illumina and Thermo Fisher Scientific also vying for market share. Despite this competition, $FLGT has seen significant growth in recent years, driven by increasing demand for genetic testing services. The company’s Q4 2025 earnings report also highlighted its commitment to research and development, with $FLGT investing $15.6 million in R&D during the quarter.
The earnings call also provided an update on $FLGT’s recent partnerships, including its collaboration with Microsoft to develop new genetic testing technologies. The partnership aims to leverage Microsoft‘s artificial intelligence capabilities to improve the accuracy and speed of genetic testing. The collaboration is seen as a key strategic move for $FLGT, as the company looks to stay ahead of the competition in the rapidly evolving genetic testing market.
| Metric | Q4 2025 | Q4 2024 |
|---|---|---|
| Revenue | $141.7 million | $116.2 million |
| Net Income | $23.4 million | $18.5 million |
| Earnings Per Share | $0.63 | $0.49 |
Looking ahead, $FLGT is expected to continue its growth trajectory, driven by increasing demand for genetic testing services and the company’s expanding product portfolio. The company’s commitment to research and development, as well as its strategic partnerships, are also expected to drive growth in the coming quarters. As the genetic testing market continues to evolve, $FLGT is well-positioned to remain a key player, with its strong financial performance and strategic initiatives setting the stage for long-term success.
⚡ Why it matters: Fulgent Genetics, Inc.’s Q4 2025 earnings report provides insight into the company’s financial performance and strategic initiatives, highlighting its growth potential in the competitive genetic testing market. The company’s commitment to research and development, as well as its strategic partnerships, are key factors driving its success.
📊 By the numbers:
Revenue: $141.7 million
Net Income: $23.4 million
Earnings Per Share: $0.63
Cash and Cash Equivalents: $135.6 million
R&D Investment: $15.6 million
🔗 Source: Fulgent Genetics, Inc. Q4 2025 Earnings Call Transcript*
